Substance / Medication

Atovaquone

Overview

Active Ingredient
atovaquone
RxNorm CUI
60212
Labeler: Kesin Pharma CorporationUpdated: 2026-02-06T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.
Blanshard Andrew, Hine Paul · Cochrane Database Syst Rev · 2021
PMID: 33459345Meta-AnalysisFull text (PMC)
Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.
Staines Henry M, Burrow Rebekah, Teo Beatrix Huei-Yi et al. · J Antimicrob Chemother · 2018
PMID: 29237012Meta-AnalysisFull text (PMC)
A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.
Nakato Halima, Vivancos Roberto, Hunter Paul R · J Antimicrob Chemother · 2007
PMID: 17848375Meta-Analysis
Atovaquone-proguanil for treating uncomplicated malaria.
Osei-Akoto A, Orton L, Owusu-Ofori S P O · Cochrane Database Syst Rev · 2005
PMID: 16235366Meta-AnalysisFull text (PMC)
Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.
Chalon Stephan, Chughlay M Farouk, Abla Nada et al. · Clin Pharmacol Ther · 2022
PMID: 34453327RCTFull text (PMC)
Re-emergence of Babesia conradae and effective treatment of infected dogs with atovaquone and azithromycin.
Di Cicco Michael F, Downey Megan E, Beeler Emily et al. · Vet Parasitol · 2012
PMID: 22305297RCT
Synthesis and comparison of in vitro dual anti-infective activities of novel naphthoquinone hybrids and atovaquone.
Erasmus Chané, Aucamp Janine, Smit Frans J et al. · Bioorg Chem · 2021
PMID: 34216896Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Atovaquone (substance)
SNOMED CT
386899002
UMLS CUI
C0165603
RxNorm CUI
60212
Labeler
Kesin Pharma Corporation

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.